WallStreetZenWallStreetZen

NASDAQ: CALC
Calcimedica Inc Stock Forecast, Predictions & Price Target

Analyst price target for CALC

Based on 4 analysts offering 12 month price targets for Calcimedica Inc.
Min Forecast
$14.00+249.13%
Avg Forecast
$19.00+373.82%
Max Forecast
$22.00+448.63%

Should I buy or sell CALC stock?

Based on 4 analysts offering ratings for Calcimedica Inc.
Strong Buy
Strong Buy
1 analysts 25%
Buy
3 analysts 75%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their CALC stock forecasts and price targets.

CALC stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2024-04-01
lockedlocked$00.00+00.00%2024-04-01
lockedlocked$00.00+00.00%2024-03-13
lockedlocked$00.00+00.00%2024-02-16

1 of 1

Forecast return on equity

Is CALC forecast to generate an efficient return?
Company
N/A
Industry
N/A
Market
35.66%

Forecast return on assets

Is CALC forecast to generate an efficient return on assets?
Company
N/A
Industry
N/A

CALC revenue forecast

What is CALC's revenue in the next 3 years based on estimates from 1 analyst?
Avg 1 year Forecast
$8.4M
Avg 2 year Forecast
$26.2M
Avg 3 year Forecast
$85.7M

CALC vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
CALC$4.01$19.00+373.82%Strong Buy
CTCX$2.25N/AN/A
BOLT$1.14$8.00+601.75%Buy
CLNN$0.33$6.00+1,718.18%Strong Buy
NXTC$1.57$6.00+282.17%Buy

Calcimedica Stock Forecast FAQ

Is Calcimedica Stock a good buy in 2024, according to Wall Street analysts?

The consensus among 4 Wall Street analysts covering (NASDAQ: CALC) stock is to Strong Buy CALC stock.

Out of 4 analysts, 1 (25%) are recommending CALC as a Strong Buy, 3 (75%) are recommending CALC as a Buy, 0 (0%) are recommending CALC as a Hold, 0 (0%) are recommending CALC as a Sell, and 0 (0%) are recommending CALC as a Strong Sell.

If you're new to stock investing, here's how to buy Calcimedica stock.

What is CALC's revenue growth forecast for 2026-2028?

(NASDAQ: CALC) Calcimedica's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.96%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.23%.

Calcimedica's revenue in 2024 is $0.On average, 1 Wall Street analysts forecast CALC's revenue for 2026 to be $90,216,966, with the lowest CALC revenue forecast at $90,216,966, and the highest CALC revenue forecast at $90,216,966. On average, 2 Wall Street analysts forecast CALC's revenue for 2027 to be $280,854,007, with the lowest CALC revenue forecast at $218,024,335, and the highest CALC revenue forecast at $343,683,680.

In 2028, CALC is forecast to generate $919,890,850 in revenue, with the lowest revenue forecast at $571,374,118 and the highest revenue forecast at $1,268,407,582.

What is CALC's forecast return on assets (ROA) for 2024-2027?

(NASDAQ: CALC) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of N/A.

What is CALC's Price Target?

According to 4 Wall Street analysts that have issued a 1 year CALC price target, the average CALC price target is $19.00, with the highest CALC stock price forecast at $22.00 and the lowest CALC stock price forecast at $14.00.

On average, Wall Street analysts predict that Calcimedica's share price could reach $19.00 by Apr 1, 2025. The average Calcimedica stock price prediction forecasts a potential upside of 373.82% from the current CALC share price of $4.01.

What is CALC's forecast return on equity (ROE) for 2024-2027?

(NASDAQ: CALC) forecast ROE is N/A, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.